Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry – Implications and Prospects
Summary This report is the third edition of our analysis of mergers and acquisitions in the contract pharmaceutical industry. PharmSource is the most definitive and reliable source of strategic information on this subject in the bio / pharmaceutical field.
New York, July 08, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry – Implications and Prospects – 2021 Edition” – https: // www. reportlinker.com/p06103613/?utm_source=GNW
This 55 page report provides important and expert information that you will not find in any other source. 28 tables and figures throughout the report illustrate the main points and trends.
This report is required reading for –
– CMOs: market trends, strategic planning, competitive intelligence, performance benchmark
– Bio / Pharma: supplier performance benchmark, market trends, competitive intelligence
– Private Equity and Stock analysts: identification and analysis of targets, benchmark of the performance of portfolio companies
Reasons to buy
– Overview of mergers and acquisitions in the CMO pharmaceutical industry
– Detailed view of CDMO performance by number of transactions concluded from the transaction database
– Analysis of mergers and acquisitions of specific manufacturing services
Read the full report: https://www.reportlinker.com/p06103613/?utm_source=GNW
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001